Profile of sarilumab and its potential in the treatment of rheumatoid arthritis

Maria Gabriella Raimondo,1 Martina Biggioggero,1 Chiara Crotti,1 Andrea Becciolini,2 Ennio Giulio Favalli2 1Department of Clinical Sciences and Health Community, Division of Rheumatology, University of Milan, 2Department of Rheumatology, Gaetano Pini Institute, Milan, Italy Abstract: In recent yea...

Full description

Bibliographic Details
Main Authors:	Raimondo MG, Biggioggero M, Crotti C, Becciolini A, Favalli EG
Format:	Article
Language:	English
Published:	Dove Medical Press 2017-05-01
Series:	Drug Design, Development and Therapy
Subjects:	rheumatoid arthritis interleukin-6 sarilumab monoclonal antibody biologic drugs
Online Access:	https://www.dovepress.com/profile-of-sarilumab-and-its-potential-in-the-treatment-of-rheumatoid--peer-reviewed-article-DDDT

Similar Items

Sarilumab: patient-reported outcomes in rheumatoid arthritis
by: Crotti C, et al.
Published: (2018-08-01)

New possibilities of drug therapy for rheumatoid arthritis: focus at sarilumab
by: D. E. Karateev, et al.
Published: (2019-11-01)

Inhibitor of biological effects of interleukin-6 sarilumab in treatment of rheumatoid arthritis
by: D. E. Karateev, et al.
Published: (2019-12-01)

Spotlight on mavrilimumab for the treatment of rheumatoid arthritis: evidence to date
by: Crotti C, et al.
Published: (2017-01-01)

The efficacy and safety of sarilumab, fully human monoclonal antibodies against interleukin 6 receptor, in rheumatoid arthritis: new evidence
by: E. L. Nasonov, et al.
Published: (2019-11-01)

Efficacy and safety of sarilumab in combination with methotrexate in patients with active rheumatoid arthritis and inadequate effect of methotrexate monotherapy (results of phase III MOBILITY study)
by: E. L. Nasonov, et al.
Published: (2019-05-01)

Efficacy and safety of sarilumab in combination with csDMARDs or as monotherapy in subpopulations of patients with moderately to severely active rheumatoid arthritis in three phase III randomized, controlled studies
by: Mark C. Genovese, et al.
Published: (2020-06-01)

High levels of interleukin-6 in patients with rheumatoid arthritis are associated with greater improvements in health-related quality of life for sarilumab compared with adalimumab
by: Vibeke Strand, et al.
Published: (2020-10-01)

Sarilumab use in severe Coronavirus Disease 2019 pneumonia
by: Ahmed M.A. El Fattah Amer, et al.
Published: (2023-01-01)

Tolerability of Sarilumab – An anti-interleukin-6 receptor monoclonal antibody is controversial for the management of COVID-19
by: Justin Jacob Abraham, et al.
Published: (2021-01-01)

Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a randomized, placebo-controlled phase III trial in Japan
by: Yoshiya Tanaka, et al.
Published: (2019-03-01)

Impact of IL6R genetic variants on treatment efficacy and toxicity response to sarilumab in rheumatoid arthritis
by: Luis Sainz, et al.
Published: (2023-11-01)

The role of concomitant methotrexate dosage and maintenance over time in the therapy of rheumatoid arthritis patients treated with adalimumab or etanercept: retrospective analysis of a local registry
by: Favalli EG, et al.
Published: (2018-05-01)

Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis
by: Vibeke Strand, et al.
Published: (2018-06-01)

Tocilizumab in the treatment of rheumatoid arthritis: an evidence-based review and patient selection
by: Biggioggero M, et al.
Published: (2018-12-01)

Sarilumab is not Inferior to Tocilizumab in the Treatment of Cytokine Release Syndrome in COVID-19
by: V. T. Ivashkin, et al.
Published: (2023-12-01)

Sarilumab and adalimumab differential effects on bone remodelling and cardiovascular risk biomarkers, and predictions of treatment outcomes
by: Cem Gabay, et al.
Published: (2020-04-01)

Association between low hemoglobin, clinical measures, and patient-reported outcomes in patients with rheumatoid arthritis: results from post hoc analyses of three phase III trials of sarilumab
by: Andrea Rubbert-Roth, et al.
Published: (2022-08-01)

Rheumatoid arthritis: current therapeutics compendium
by: Dariushnejad Hassan, et al.
Published: (2022-04-01)

Upadacitinib and filgotinib: the role of JAK1 selective inhibition in the treatment of rheumatoid arthritis
by: Martina Biggioggero, et al.
Published: (2019-10-01)

Clinical Efficacy of Sarilumab Versus Upadacitinib Over 12 weeks: An Indirect Treatment Comparison
by: Thomas Huizinga, et al.
Published: (2023-02-01)

Case of successful use of sarilumab in secondary renal amyloidosis in a patient with rheumatoid arthritis
by: L. A. Smirnova, et al.
Published: (2022-11-01)

A phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of sarilumab in patients with giant cell arteritis
by: Wolfgang A. Schmidt, et al.
Published: (2023-10-01)

Effects of the Interleukin-6 Receptor Blocker Sarilumab on Metabolic Activity and Differentiation Capacity of Primary Human Osteoblasts
by: Annett Klinder, et al.
Published: (2022-06-01)

Immunogenicity of Sarilumab Monotherapy in Patients with Rheumatoid Arthritis Who Were Inadequate Responders or Intolerant to Disease-Modifying Antirheumatic Drugs
by: Alvin F. Wells, et al.
Published: (2019-05-01)

Sarilumab Administration in COVID-19 Patients: Literature Review and Considerations
by: Andrea Marino, et al.
Published: (2022-05-01)

Polymyalgia Rheumatica Treated with Sarilumab
by: Anvitha Madhavaram, et al.
Published: (2023-12-01)

DIAGNOSTIC MARKERS AND CYTOKINE PROFILE IN PATIENTS WITH RHEUMATOID ARTHRITIS RECEIVING DMARDS
by: Maria Sergeevna Voronina, et al.
Published: (2012-10-01)

Spotlight on sirukumab for the treatment of rheumatoid arthritis: the evidence to date
by: Lazzerini PE, et al.
Published: (2016-09-01)

Efficacy and safety of levilimab in combination with methotrexate in subjects with rheumatoid arthritis: Results of phase II AURORA study
by: V. I. Mazurov, et al.
Published: (2021-05-01)

The prospects of interleukin-6 inhibition in rheumatoid arthritis: Olokizumab (novel monoclonal antibodies to IL-6)
by: E. L. Nasonov, et al.
Published: (2022-11-01)

Datasets of YY1 expression in rheumatoid arthritis patients
by: Jinpiao Lin, et al.
Published: (2016-12-01)

Cytokine Profile in Patients with Rheumatoid Arthritis
by: Falah S. Manhal
Published: (2010-01-01)

Efficacy and safety of levilimab in combination with methotrexate in patients with active rheumatoid arthritis: 56-week results of phase III randomized double-blind placebo-controlled trial SOLAR
by: V. I. Mazurov, et al.
Published: (2023-03-01)

Primary pathologic role of interleukin-6 in rheumatoid arthritis
by: G.L. Bajocchi, et al.
Published: (2013-05-01)

The long-term remission of rheumatoid arthritis with a single cycle of rituximab
by: Glišić Branislava, et al.
Published: (2012-01-01)

Sirukumab in rheumatoid arthritis refractory to sulfasalazine or methotrexate: a randomized phase 3 safety and efficacy study in Japanese patients
by: Tsutomu Takeuchi, et al.
Published: (2018-03-01)

Rituximab treatment of rheumatoid arthritis: new evidence
by: E L Nasonov, et al.
Published: (2009-06-01)

Pharmacogenomics of Monoclonal Antibodies for the Treatment of Rheumatoid Arthritis
by: Sung Ho Lim, et al.
Published: (2022-07-01)

Sarilumab use in severe SARS-CoV-2 pneumonia
by: Elisa Gremese, et al.
Published: (2020-10-01)